Aspect Biosystems
Develops bioprinted human tissues designed to replace, repair, or supplement biological function.
From Lab Bench to Lifeline: Why Aspect Biosystems' Deep Tech Bioprinting Platform Signals a New Era for Canadian Regenerative Medicine
As a Canadian tech enthusiast, the latest $280 million federal support package for Aspect Biosystems is more than just a funding announcement—it's a powerful indicator of maturity and conviction in Canada’s de...
↗ Aspect's strength lies not just in 3D printing, but in its proprietary, full-stack platform that combines advanced bioengineering, specialized biomaterials, and clinical manufacturing expertise. This deep integration of technology and biology positions them to solve chronic metabolic diseases in a uniquely Canadian setting, making them a global benchmark for regenerative medicine.
UBC Catalyst Fund Ushers in a New Era for BC Deep Tech, Grounded by Aspect Biosystems’ Vision
The commitment of $20 million each from UBC and InBC Investment Corp. for the UBC Catalyst Ventures Fund is more than just a financial injection; it’s a strategic declaration of intent. It signals that British...
↗ The UBC Catalyst Ventures Fund, backed by significant public and private capital, represents a pivotal moment for BC deep tech. By strategically combining world-class academic research (UBC) with venture capital muscle (InBC), and utilizing a vertically integrated platform leader like Aspect Biosystems, BC is building a resilient, self-sustaining engine designed to turn foundational scientific discoveries into transformative, commercialized therapies.